ストックスクリーナーアプリを入手
11.67
0.26%
-0.03
アフターアワーズ：
11.72
0.05
+0.43%
前日終値:
$11.70
開ける：
$11.7577
24時間の取引高:
1,105
Relative Volume:
0.31
時価総額：
$N/A
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-2.61%
1か月 パフォーマンス:
-7.79%
6か月 パフォーマンス:
-25.10%
1年 パフォーマンス:
-13.75%
1日の値動き範囲:
$11.67
$11.76
1週間の範囲:
$11.38
$11.98
52週間の値動き範囲:
$11.38
$17.96
Range Cancer Therapeutics Etf Stock (CNCR) Company Profile
CNCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CNCR
Range Cancer Therapeutics Etf
|
11.67 | 0 | 0 | 0 | 0 | 0.00 |
|
VTI
Vanguard Total Stock Market Etf
|
296.20 | 417.53B | 0 | 0 | 0 | 0.00 |
|
SPY
Spdr S P 500 Etf Trust
|
597.58 | 372.57B | 0 | 0 | 0 | 0.00 |
|
IVV
Ishares Core S P 500 Etf
|
600.26 | 253.41B | 0 | 0 | 0 | 0.00 |
|
VB
Vanguard Small Cap Etf
|
248.52 | 160.59B | 0 | 0 | 0 | 0.00 |
|
QQQ
Invesco Qqq Trust Series 1
|
521.74 | 124.43B | 0 | 0 | 0 | 0.00 |
Range Cancer Therapeutics Etf (CNCR) 最新ニュース
NEW: The Most Popular Sponsored Content of 2024 - Visual Capitalist
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
(CNCR) Investment Analysis - Stock Traders Daily
7 Best-Performing Biotech ETFs for January 2025 - NerdWallet
Total World Stock Index ETF Vanguard (VT-A) QuotePress Release - The Globe and Mail
Chevron Corp (CVX-N) QuotePress Release - The Globe and Mail
Texas Instruments (TXN-Q) QuotePress Release - The Globe and Mail
Pfizer Inc (PFE-N) QuotePress Release - The Globe and Mail
When the Price of (CNCR) Talks, People Listen - Stock Traders Daily
Cutaneous T-Cell Lymphoma Diagnosis Market Set to Surpass US$ 425.8 Million by 2034, States Fact.MR - GlobeNewswire Inc.
(CNCR) Trading Report - Stock Traders Daily
Enbridge Inc (ENB-N) QuotePress Release - The Globe and Mail
Cold Spring Harbor Laboratory - TBR News Media
Regeneron Pharmaceuticals, Inc. (REGN): Among the Most Promising Cancer Stocks According to Hedge Funds - MSN
Daniel Dunaief - TBR News Media
10 Most Promising Cancer Stocks According to Hedge Funds - Insider Monkey
Disruptive Theme of the Week: Breakthroughs in Medicine - ETF Trends
CSHL and Range ETFs launch new partnership - Cold Spring Harbor Laboratory
(CNCR) Long Term Investment Analysis - Stock Traders Daily
Trackinsight ETF data from 11th to 15th November, 2024 - ETF Express
The Best Biotech Stocks to Buy - Morningstar
Charted: Cancer Survival Rates Over Time - Visual Capitalist
Range Cancer Therapeutics - TBR News Media
How this award-winning TV host is setting the stage to help protect her health - TBR News Media
Investment fund pledges revenues in cancer research partnership with CSHL - TBR News Media
(CNCR) Trading Signals - Stock Traders Daily
At a Glance: Nov. 6 - Crain's New York Business
The 5 Best Biotech ETFs of 2024 - TradingView
Seagen’s Ex-CEO Starts Company to Develop Drug Tackling Wide Range of Cancers - BNN Bloomberg
SPDR Galaxy Hedged Digital Asset Ecosystem ETF (HECO-Q) QuotePress Release - The Globe and Mail
Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail
Science & Technology - TBR News Media
(CNCR) Investment Report - Stock Traders Daily
How are ADC drug partnerships changing China’s biotech landscape? - Invesco
5 Small-cap Biotech ETFs to Watch (Updated 2024) - Investing News Network
4 Cancer Stocks to Consider in 2024 - The Motley Fool
The Zacks Analyst Blog SFYX, CNCR, FXN and DIV - Yahoo Finance
4 Solid ETFs Under $20 for Your Portfolio - Yahoo Finance
Summit Therapeutics: Cancer Drug With Great Potential On 'Fast Track' To US Market (SMMT) - Seeking Alpha
Trackinsight ETF data from 23rd to 27th September, 2024 - ETF Express
(CNCR) Investment Analysis and Advice - Stock Traders Daily
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects (NASDAQ:ACRV) - Seeking Alpha
7 Top Gene-Editing Stocks to Buy | Investing - U.S News & World Report Money
Roundhill Investments Surpasses $2 Billion AUM Milestone – Company Announcement - Financial Times
5 ETFs That Led the Rebound on Monday - Yahoo Finance
IPO Roundup: Bicara Therapeutics, Kairos Pharma and more (NYSEARCA:IPO) - Seeking Alpha
Trading (CNCR) With Integrated Risk Controls - Stock Traders Daily
Cellectis: Cheap With Promising But Speculative Cancer Therapies (NASDAQ:CLLS) - Seeking Alpha
Best-Performing ETF Areas of Past Week - MSN
Range Cancer Therapeutics Etf (CNCR) 財務データ
Range Cancer Therapeutics Etf (CNCR) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
0.56%
大文字化:
|
ボリューム (24 時間):